Skip to Content

What is Rydapt used to treat?

Medically reviewed by Drugs.com Last updated on Jun 25, 2019.

Official Answer

by Drugs.com

Rydapt (midostaurin) from Novartis Pharmaceuticals is an oral, multi-targeted kinase inhibitor approved to treat acute myeloid leukemia (AML). Rydapt is for patients who have been newly-diagnosed with an FMS-like tyrosine kinase-3 (FLT3) mutation, and can be used to treat advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and mast cell leukemia.

Related Medical Questions

Drug Information

Related Support Groups

Hide